MJardin Group, Inc.

OTC: MJARF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Toronto, ONReports USD

#645 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

——

FH —DQ —GM —SS 29

v0.1 · 5/100 weight · pillars only

↑ return on assets, growth stability · ↓ revenue growth (YoY), market scale

Methodology →

Revenue TTM

$4.8M

Rev growth YoY (TTM)

-39.0%

Net income (FY)

-$26.0M

Employees

—

Market cap

$90.1k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$8.5M11.4M CAD2020

Net income-$26.0M-34.8M CAD2020

Operating income-$10.9M-14.6M CAD2020

Total assets$79.2M100.8M CAD2020

Liabilities$149.7M190.5M CAD2020

Equity-$67.6M-86.0M CAD2020

Revenue trend

FY2017 – FY2020 · USD

$15.4M

FY17

$21.2M

FY18

$20.1M

FY19

$8.5M

FY20

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

MJardin Group, Inc. booked $8.5M in FY2020 revenue, contracting 58% year over year — slower than 84% of Healthcare companies we track, at a -304.6% net margin.

Peers · Healthcare

MedGen, Inc.——Innovative MedTech Inc.49D Drug Free Solution, Inc.——Newtopia Inc.——

Key facts

CEOAli Mahdavi

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersToronto, ON

ExchangeOTC: MJARF

Employees—

IPO date2018-11-16

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.